This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

Source The Motley Fool

Vaccine maker Novavax (NASDAQ: NVAX) has had a rollercoaster of a year. In May, the company's shares soared after it announced a lucrative agreement with biotech giant Sanofi. It's been mostly downhill for Novavax since then, though that's likely due to some profit taking by investors.

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock price is still up by more than 100% for the year, but this sell-off could represent an opportunity for long-term investors, provided Novavax can turn things around. Is that likely to happen?

Let's find out.

NVAX Chart

NVAX data by YCharts

Novavax's late-stage trials hit a snag

Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on two other candidates. One is an investigational influenza vaccine. The other is a potential combination coronavirus/flu vaccine. It planned on starting phase 3 clinical trials for both in the fourth quarter.

This plan is now in doubt. The company just announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its Investigational New Drug (IND) application for these candidates. Biotechs must submit INDs before being allowed to proceed with clinical trials. The FDA's clinical hold is based on safety concerns. There was a report of a severe adverse event in a patient in one of Novavax's phase 2 studies who experienced nerve damage.

So where does Novavax go from here?

The bigger picture

Investigators have not established that Novavax's vaccine caused this adverse event. As the company notes, this is just a single case that was reported more than a year after the trial was completed. That doesn't mean there is no causal link, but let's not jump to conclusions. It is out of an abundance of caution that regulators opt to place investigational vaccines or medicines on clinical hold in cases like these. Better safe than sorry, as the saying goes.

The problem for Novavax is that the market doesn't like uncertainty. The longer this clinical hold drags on -- and no one knows whether or when it will be lifted -- the more anxious investors will get. So, if the company can't resolve things relatively quickly, its stock price could continue to sink, especially since it might delay the projected launch date of these candidates.

Novavax wanted to run late-stage clinical trials starting in the fourth quarter, that is, during this fall/winter season -- that's peak vaccine season for the flu. The company planned to release data in mid-2025, which means it had a chance to earn approval for these vaccines by mid-2026. Unless it can get over this hump quickly, its carefully crafted plan could get pushed back by as much as a year or more, even if it turns out that its vaccine wasn't responsible for the adverse event.

What should investors do? In my view, Novavax wasn't a particularly attractive stock even before this setback. True, the company's partnership with Sanofi gave it a lifeline. But Novavax's COVID-19 vaccine -- whose commercialization rights Sanofi will soon own in most countries -- continues to be a distant third in the U.S. market.

Novavax's combined coronavirus/flu candidate looks promising since many patients would prefer this option over getting two shots to be inoculated against COVID-19 and the flu. Others are working on similar projects, though, so Novavax would face stiff competition from companies with much bigger pockets. That includes Moderna, whose combination vaccine recently aced a phase 3 study, Pfizer, and more.

Novavax could still be successful despite the competition. But then you have to factor in all the risks involved, including potential clinical and regulatory setbacks and the real possibility that even if its candidates made it to the market, they wouldn't be as successful as the company hoped.

This clinical hold only reinforces one vital point: Biotech companies, especially relatively small ones, face meaningful risks related to unforeseen clinical setbacks. So, no matter how promising their candidates look, factoring that in is crucial. Novavax might resolve this issue pretty quickly. If I were a betting man, I'd say that's the most likely outcome. But I'd still advise long-term investors to avoid the stock anyway.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $21,285!*
  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $44,456!*
  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $411,959!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of October 14, 2024

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Ethereum Price Drops Back: Another Test for Support LevelsEthereum price failed to clear the $3,750 resistance and trimmed gains. ETH is back to $3,350 and might struggle to start a fresh increase. Ethereum started a fresh decline from the $3,750 zone. The
Author  NewsBTC
Jan 08, Wed
Ethereum price failed to clear the $3,750 resistance and trimmed gains. ETH is back to $3,350 and might struggle to start a fresh increase. Ethereum started a fresh decline from the $3,750 zone. The
placeholder
Bitcoin Outlook 2025As the Bitcoin market continues to mature, its 2025 outlook appears highly favourable, driven by institutional adoption and regulatory developments.
Author  TradingKey
Jan 23, Thu
As the Bitcoin market continues to mature, its 2025 outlook appears highly favourable, driven by institutional adoption and regulatory developments.
placeholder
What Crypto Whales are Buying For May 2025Crypto whales are making bold moves heading into May 2025, and three tokens are standing out: Ethereum (ETH), Artificial Superintelligence Alliance (FET), and Onyxcoin (XCN).
Author  Beincrypto
Apr 21, Mon
Crypto whales are making bold moves heading into May 2025, and three tokens are standing out: Ethereum (ETH), Artificial Superintelligence Alliance (FET), and Onyxcoin (XCN).
placeholder
Ethereum Price Ready to Surge—$2,000 Level Could Be Within ReachEthereum price started a fresh increase above the $1,800 zone. ETH is now rising and attempting a move above the $1,850 resistance. Ethereum started a fresh recovery wave above the $1,820 resistance.
Author  NewsBTC
May 08, Thu
Ethereum price started a fresh increase above the $1,800 zone. ETH is now rising and attempting a move above the $1,850 resistance. Ethereum started a fresh recovery wave above the $1,820 resistance.
placeholder
Ethereum Price Explodes Past $2,200 with 25% Surge—Momentum Builds FastEthereum price started a fresh surge above the $2,000 zone. ETH is now up over 25% and consolidating gains near the $2,200 zone. Ethereum started a fresh surge above the $2,000 resistance.
Author  NewsBTC
May 09, Fri
Ethereum price started a fresh surge above the $2,000 zone. ETH is now up over 25% and consolidating gains near the $2,200 zone. Ethereum started a fresh surge above the $2,000 resistance.
goTop
quote